Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

NCT03203590 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

590

Enrollment

OTHER

Sponsor class

Conditions

2-year Disease-Free Survival

Interventions

DRUG: Oral Navelbine + Carboplatin
DRUG: Gefitinib

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]